SC-10914

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameSC-10914
Drug Alias NameSC-10914
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitors
TargetsPoly (ADP-Ribose) polymerase
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangxi Qingfeng Medicine Group Co LtdShanghai De Novo Pharmatech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai De Novo Pharmatech Co LtdJiangxi Qingfeng Pharmaceutical Industry Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursProstatic Neoplasms, Castration-Resistant +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A